Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Product	$ 669,000	$ 466,000
License	144,000	1,216,000
Contract research and government grants	2,375,000	3,732,000
Total revenues (which includes $0 and $91 from related parties — Note 16)	3,188,000	5,414,000
Operating expenses:
Cost of product revenues	895,000	892,000
Research and development	8,663,000	8,966,000
Selling, general and administrative	12,250,000	11,119,000
Total operating expenses	21,808,000	20,977,000
Loss from operations	(18,620,000)	(15,563,000)
Interest expense	(1,319,000)	(2,658,000)
Other income, net	340,000	521,000
Loss on extinguishment of debt	0	(230,000)
Net loss before income taxes	(19,599,000)	(17,930,000)
Income tax provision	(25,000)	(26,000)
Net loss	(19,624,000)	(17,956,000)
Accretion of redeemable convertible preferred stock to redemption value		(2,574,000)
Deemed dividends to warrant holder		(197,000)
Net loss attributable to common stockholders	$ (19,624,000)	$ (20,727,000)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.44)	$ (0.73)
Weighted-average number of shares used in per share calculations:
Basic and diluted	44,366,816	28,559,119
Other comprehensive income (loss), net of tax
Unrealized gains (losses) on available-for-sale securities	$ 96,000	$ (115,000)
Other comprehensive income (loss)	96,000	(115,000)
Comprehensive loss attributable to common stockholders	$ (19,528,000)	$ (20,842,000)